NCT06993844: An ongoing trial by Ensem Therapeutics
This trial is ongoing. It must report results 2 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06993844 |
|---|---|
| Title | A Phase 1/2, Open-label, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-mutant-selective PI3Kα Inhibitor, as Monotherapy and in Combination With Other Anticancer Therapies in Participants With Advanced Solid Tumors |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 10, 2025 |
| Completion date | June 30, 2027 |
| Required reporting date | June 29, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 19, 2026 |
| Days late | None |